New hope for amyloidosis patients: experimental antibody therapy trial opens
NCT ID NCT07151690
Summary
This study is testing a new antibody treatment called CM336 for people newly diagnosed with systemic light chain amyloidosis, a serious disease where abnormal proteins build up in organs. The trial will enroll 21 participants at a single hospital in China to see how well the treatment works and how safe it is. Researchers will measure how much the treatment reduces the harmful proteins and monitor side effects.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SYSTEMIC LIGHT CHAIN AMYLOIDOSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Institute of Hematology and Blood Diseases Hospital Chinese Academy of Medical Sciences
RECRUITINGTianjin, 300000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.